GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Book Value per Share

HilleVax (HilleVax) Book Value per Share : $5.57 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is HilleVax Book Value per Share?

HilleVax's book value per share for the quarter that ended in Dec. 2023 was $5.57.

During the past 12 months, HilleVax's average Book Value Per Share Growth Rate was -21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

HilleVax's current price is $13.84. Its book value per share for the quarter that ended in Dec. 2023 was $5.57. Hence, today's PB Ratio of HilleVax is 2.48.

During the past 4 years, the highest P/B Ratio of HilleVax was 3.19. The lowest was 0.00. And the median was 0.00.


HilleVax Book Value per Share Historical Data

The historical data trend for HilleVax's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Book Value per Share Chart

HilleVax Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Book Value per Share
-0.17 -3.34 7.10 5.57

HilleVax Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.10 6.42 5.58 6.30 5.57

Competitive Comparison of HilleVax's Book Value per Share

For the Biotechnology subindustry, HilleVax's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HilleVax's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HilleVax's PB Ratio distribution charts can be found below:

* The bar in red indicates where HilleVax's PB Ratio falls into.



HilleVax Book Value per Share Calculation

HilleVax's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(265.53-0.00)/47.67
=5.57

HilleVax's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(265.53-0.00)/47.67
=5.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


HilleVax  (NAS:HLVX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


HilleVax Book Value per Share Related Terms

Thank you for viewing the detailed overview of HilleVax's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax (HilleVax) Business Description

Traded in Other Exchanges
N/A
Address
75 State Street, Suite 100 - No. 9995, Boston, MA, USA, 02109
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Executives
Astrid Borkowski officer: Chief Medical Officer C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Shane Maltbie officer: Chief Financial Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda director C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu director ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aditya Kohli director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
David A Socks officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668